NasdaqGS - Nasdaq Real Time Price USD

Biogen Inc. (BIIB)

191.95 -17.08 (-8.17%)
At close: July 14 at 4:00:01 PM EDT
189.66 -2.29 (-1.19%)
Pre-Market: 4:05:52 AM EDT
Trade Biogen on Coinbase
Chart Range Bar
Loading chart for BIIB

Why is BIIB moving today? Biogen (BIIB) remained flat today as mixed reactions to recent Alzheimer’s drug trial results left investors cautious, while the broader healthcare sector also showed no movement.

Biogen (BIIB) remained flat today as mixed reactions to recent Alzheimer’s drug trial results left investors cautious, while the broader healthcare sector also showed no movement.

Updated 16m ago · Powered by Yahoo Scout
  • Previous Close 209.03
  • Open 200.34
  • Bid 184.67 x 100
  • Ask 203.96 x 100
  • Day's Range 189.40 - 201.90
  • 52 Week Range 121.05 - 219.72
  • Volume 3,902,309
  • Avg. Volume 1,201,136
  • Market Cap (intraday) 28.339B
  • Beta (5Y Monthly) 0.16
  • PE Ratio (TTM) 22.48
  • EPS (TTM) 8.54
  • Earnings Date Jul 29, 2026
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 224.45

Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE. It offers LEQEMBI for the treatment of Alzheimer's disease; ZURZUVAE for the treatment of postpartum depression; RITUXAN to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for aRelapsed or refractory diffuse large B-cell lymphoma; and other anti-CD20 therapies. Biogen Inc. has collaboration and license agreements with Merz Therapeutics; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; UCB; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis; and Sage Therapeutics, Inc., as well as collaborations with Stoke Therapeutics, Inc. for the development and commercialization of zorevunersen, a disease modifying medicine for the treatment of Dravet syndrome; Dayra Therapeutics, Inc. to develop oral macrocyclic peptides; Vanqua Bio, Inc. for developing Vanqua's preclinical oral C5aR1 antagonist compound; City Therapeutics, Inc. to develop select novel RNAi therapies; and ALTEOGEN Inc. to develop subcutaneous (SC) formulations of biologics utilizing ALT-B4. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

www.biogen.com

7,500

Full Time Employees

December 31

Fiscal Year Ends

Performance Overview

Trailing total returns as of 7/14/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

BIIB
9.07%
S&P 500 (^GSPC)
10.20%

1-Year Return

BIIB
44.20%
S&P 500 (^GSPC)
20.34%

3-Year Return

BIIB
31.18%
S&P 500 (^GSPC)
67.43%

5-Year Return

BIIB
45.48%
S&P 500 (^GSPC)
72.45%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized
 

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q1 FY26
Revenue 2.48B
Earnings 529.1M

Q2

FY25

Q3

FY25

Q4

FY25

Q1

FY26

0
500M
1B
2B
2B
3B
 

Analyst Insights

View More

Top Analyst

Jefferies
57/100
Latest Rating
Buy
 

Analyst Price Targets

157.00 Low
224.45 Average
191.95 Current
300.00 High
 

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell
 

Latest Rating

Date 7/13/2026
Analyst Truist Securities
Rating Action Upgrade
Rating Buy
Price Action Raises
Price Target 190 -> 235
 

Statistics

View More

Valuation Measures

Annual
As of 7/13/2026
  • Market Cap

    30.86B

  • Enterprise Value

    33.14B

  • Trailing P/E

    22.48

  • Forward P/E

    14.97

  • PEG Ratio (5yr expected)

    4.40

  • Price/Sales (ttm)

    3.10

  • Price/Book (mrq)

    1.65

  • Enterprise Value/Revenue

    3.33

  • Enterprise Value/EBITDA

    12.28

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    13.81%

  • Return on Assets (ttm)

    5.95%

  • Return on Equity (ttm)

    7.70%

  • Revenue (ttm)

    9.94B

  • Net Income Avi to Common (ttm)

    1.37B

  • Diluted EPS (ttm)

    8.54

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    4.28B

  • Total Debt/Equity (mrq)

    35.18%

  • Levered Free Cash Flow (ttm)

    1.93B

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights

Fair Value

191.95 Current
 

Dividend Score

0 Low
Sector Avg.
100 High
 

Hiring Score

0 Low
Sector Avg.
100 High
 

Insider Sentiment Score

0 Low
Sector Avg.
100 High
 

Research Reports

View More
  • Biogen is a biotech company that develops, manufactures, and sells therapies for treating neurological and neurodegenerative diseases. The company is the market leader in MS drugs and launched the first approved treatments for spinal muscular atrophy and AD. The company also sells products that treat plaque psoriasis, non-Hodgkin's lymphoma, lymphocytic leukemia, and rheumatoid arthritis. Current research continues on MS and has expanded to include neuroimmunology, ophthalmology, lupus, and other neuromuscular and movement disorders. Founded in 1978, the company is located in Cambridge, Massachusetts; employs 7,500 people; and is a component of the S&P 500.

    Biogen is a biotech company that develops, manufactures, and sells therapies for treating neurological and neurodegenerative diseases. The company is the market leader in MS drugs and launched the first approved treatments for spinal muscular atrophy and AD. The company also sells products that treat plaque psoriasis, non-Hodgkin's lymphoma, lymphocytic leukemia, and rheumatoid arthritis. Current research continues on MS and has expanded to include neuroimmunology, ophthalmology, lupus, and other neuromuscular and movement disorders. Founded in 1978, the company is located in Cambridge, Massachusetts; employs 7,500 people; and is a component of the S&P 500.

    Rating
     
  • There are no summer doldrums this week as earnings season blasts off with the country's biggest banks in focus. Inflation data is also pending and Kevin Warsh will give his first Congressional testimony as Fed chief. Last week, the Dow Jones Industrial Average was down 1%, the S&P 500 gained 1%, and the Nasdaq rose 2%. Year to date, all three indices are in positive territory, with the DJIA up 10%, the S&P 500 11%, and the Nasdaq 13%. Earnings headliners this week include JP Morgan, Citigroup, Bank of America, Goldman Sachs, and Wells Fargo on Tuesday; Johnson & Johnson, Morgan Stanley, BlackRock, Bank of New York Mellon, and PNC Financial on Wednesday; Taiwan Semiconductor, UnitedHealth, General Electric, and Netflix on Thursday; and Travelers and Truist Financial on Friday. The economic calendar includes inflation indicator CPI (Consumer Price Index) on Tuesday, followed by wholesale price indicator PPI (Producer Price Index) on Wednesday. Retail Sales will be reported on Thursday, and Housing Starts, Building Permits, Industrial Production, and Capacity Utilization on Friday. On Wednesday, Federal Reserve Chairman Kevin Warsh testifies to both houses of Congress (the House on Tuesday and the Senate on Wednesday). Other Fed officials also are out and about speaking publicly this week. Gas prices continue to drop, off another five cents last week. Elsewhere, the Atlanta Fed GDPNow forecast calls for 1.3% GDP growth in 2Q, unchanged from last week but down from 3.0% a few weeks ago. The Cleveland Fed Inflation Nowcast for CPI is at 3.9% for June and 3.7% for July, up from last week's estimate of 3.5%. Mortgage rates rose six basis points last week, with the average 30-year fixed-rate mortgage now at 6.49%, according to FreddieMac. The next Federal Open Market Committee (FOMC) meeting is on July 29 and odds for a rate hike at that meeting are now at 32%. Taking a deeper dive into performance so far in 2026, a leading industrialized global stock market index, the ETF EFA, is up 8% year to date, while the leading emerging market ETF (EEM) is up 22%. U.S. growth stocks are up 4% year to date when looking at ETF IWF, while value stocks (IWD) are up 17%. Crude oil was at $72 per barrel on Friday, up 23% for the year. In other asset classes for the year to date, AGG bonds are down 2%, gold is down 6%, and Bitcoin is down 27%. The U.S. dollar is up 3%, tracking DXY. The VIX Volatility Index was about 15 on Friday, below its historical average of 20. Turning to sector performance, the list from first to worst so far in 2026 is Information Technology (+29%), Energy (+23%), Industrials (+17%), Materials (+11%), Real Estate (+10%), Consumer Staples (+7%), Utilities (+6%), Healthcare (+5%), Financials (+1%), Consumer Discretionary (-2%), and Communication Services (-6%).

    There are no summer doldrums this week as earnings season blasts off with the country's biggest banks in focus. Inflation data is also pending and Kevin Warsh will give his first Congressional testimony as Fed chief. Last week, the Dow Jones Industrial Average was down 1%, the S&P 500 gained 1%, and the Nasdaq rose 2%. Year to date, all three indices are in positive territory, with the DJIA up 10%, the S&P 500 11%, and the Nasdaq 13%. Earnings headliners this week include JP Morgan, Citigroup, Bank of America, Goldman Sachs, and Wells Fargo on Tuesday; Johnson & Johnson, Morgan Stanley, BlackRock, Bank of New York Mellon, and PNC Financial on Wednesday; Taiwan Semiconductor, UnitedHealth, General Electric, and Netflix on Thursday; and Travelers and Truist Financial on Friday. The economic calendar includes inflation indicator CPI (Consumer Price Index) on Tuesday, followed by wholesale price indicator PPI (Producer Price Index) on Wednesday. Retail Sales will be reported on Thursday, and Housing Starts, Building Permits, Industrial Production, and Capacity Utilization on Friday. On Wednesday, Federal Reserve Chairman Kevin Warsh testifies to both houses of Congress (the House on Tuesday and the Senate on Wednesday). Other Fed officials also are out and about speaking publicly this week. Gas prices continue to drop, off another five cents last week. Elsewhere, the Atlanta Fed GDPNow forecast calls for 1.3% GDP growth in 2Q, unchanged from last week but down from 3.0% a few weeks ago. The Cleveland Fed Inflation Nowcast for CPI is at 3.9% for June and 3.7% for July, up from last week's estimate of 3.5%. Mortgage rates rose six basis points last week, with the average 30-year fixed-rate mortgage now at 6.49%, according to FreddieMac. The next Federal Open Market Committee (FOMC) meeting is on July 29 and odds for a rate hike at that meeting are now at 32%. Taking a deeper dive into performance so far in 2026, a leading industrialized global stock market index, the ETF EFA, is up 8% year to date, while the leading emerging market ETF (EEM) is up 22%. U.S. growth stocks are up 4% year to date when looking at ETF IWF, while value stocks (IWD) are up 17%. Crude oil was at $72 per barrel on Friday, up 23% for the year. In other asset classes for the year to date, AGG bonds are down 2%, gold is down 6%, and Bitcoin is down 27%. The U.S. dollar is up 3%, tracking DXY. The VIX Volatility Index was about 15 on Friday, below its historical average of 20. Turning to sector performance, the list from first to worst so far in 2026 is Information Technology (+29%), Energy (+23%), Industrials (+17%), Materials (+11%), Real Estate (+10%), Consumer Staples (+7%), Utilities (+6%), Healthcare (+5%), Financials (+1%), Consumer Discretionary (-2%), and Communication Services (-6%).

     
  • Biogen is a biotech company that develops, manufactures, and sells therapies for treating neurological and neurodegenerative diseases. The company is the market leader in MS drugs and launched the first approved treatments for spinal muscular atrophy and AD. The company also sells products that treat plaque psoriasis, non-Hodgkin's lymphoma, lymphocytic leukemia, and rheumatoid arthritis. Current research continues on MS and has expanded to include neuroimmunology, ophthalmology, lupus, and other neuromuscular and movement disorders. Founded in 1978, the company is located in Cambridge, Massachusetts, employs 7,500 people, and is a component of the S&P 500.

    Biogen is a biotech company that develops, manufactures, and sells therapies for treating neurological and neurodegenerative diseases. The company is the market leader in MS drugs and launched the first approved treatments for spinal muscular atrophy and AD. The company also sells products that treat plaque psoriasis, non-Hodgkin's lymphoma, lymphocytic leukemia, and rheumatoid arthritis. Current research continues on MS and has expanded to include neuroimmunology, ophthalmology, lupus, and other neuromuscular and movement disorders. Founded in 1978, the company is located in Cambridge, Massachusetts, employs 7,500 people, and is a component of the S&P 500.

    Rating
     
  • The major indices have bounced about today, initially mixed on U.S./Iran ceasefire hopes that turned into ceasefire worries, then lower on hot inflation data (which dampened the outlook for a cut in interest rates), and now higher again on renewed hopes for an ingoing ceasefire. Keep you belts fastened folks, although we note that the VIX volatility index thankfully has fallen back to about 20 after rising above 27 earlier in the week. Meanwhile, crude oil is at about $99/barrel, up from $97 earlier in the day but better than $116 earlier in the week.

    The major indices have bounced about today, initially mixed on U.S./Iran ceasefire hopes that turned into ceasefire worries, then lower on hot inflation data (which dampened the outlook for a cut in interest rates), and now higher again on renewed hopes for an ingoing ceasefire. Keep you belts fastened folks, although we note that the VIX volatility index thankfully has fallen back to about 20 after rising above 27 earlier in the week. Meanwhile, crude oil is at about $99/barrel, up from $97 earlier in the day but better than $116 earlier in the week.

     

People Also Watch